Year: 2022









CAF Board Exec Maria Hadjidemetriou Represents Thalassemia Community in Maybelline Campaign

CAF Board Exec Maria Hadjidemetriou stars in Maybelline's "We Speak" diversity campaign.

When Maybelline, the iconic beauty brand behind Maria’s first blush, invited her to star in their “We Speak” disability pride campaign, she seized the opportunity to become the very thing she longed to see as a child—a model proudly representing the thalassemia community.

Read more


FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia

zynteglo approved for beta-thalassemia

bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.

Read more


Secured By miniOrange